Zentek Ltd Stock Price, News & Analysis

Zentek (NASDAQ: ZTEK) held its annual and special meeting on September 25, 2025, where shareholders approved all proposed resolutions. The meeting resulted in the election of four board directors: Eric Wallman (97.16% approval), John Snisarenko (97.22%), Matt Fontes (72.51%), and Pete Gettinby (74.65%).

Shareholders also approved the appointment of BDO Canada LLP as auditors with 97.15% support and confirmed the company's omnibus long-term incentive plan with 87.41% approval. Following the meeting, John Snisarenko was appointed as the new Board Chair, replacing Eric Wallman, who will continue serving as Board Secretary and Chair of the Audit and Governance Committees.

Zentek (NASDAQ:ZTEK) provided a comprehensive corporate update covering multiple business segments. The company announced a CEO transition with CFO Wendy Ford appointed as Interim CEO following Greg Fenton's resignation. Their flagship product, ZenGUARD™ Enhanced Air Filters, demonstrated superior performance with 42% infectious aerosol removal efficiency compared to 16% for untreated filters.

The company is expanding globally, with strategic partnerships in Canada, Middle East, India, and South America. A significant milestone was achieved at Albany Graphite Corp., which purified graphite to 99.9992% (5N) purity, meeting nuclear industry standards. Additionally, Triera Biosciences reported promising preliminary results from in vivo testing of their H5N1 aptamer candidate, showing 5x greater survival rates and 80% less weight loss in test subjects.

Zentek (NASDAQ:ZTEK) announced that its subsidiary Albany Graphite Corp. (AGC) has achieved significant milestones in graphite purification. Working with American Energy Technologies Company (AETC), they successfully purified a second batch of Albany graphite to an ultra-high 5N purity level of 99.9992 wt.% C.

The material achieved an Equivalent Boron Concentration (EBC) of 2.60 ppm, below the 3 ppm nuclear industry requirement. This breakthrough was achieved using AETC's Fluidized Bed Reactor (FBR) purification process at 2,800°C without halogen gases, demonstrating potential for nuclear and battery applications.

The company is conducting additional testing for nuclear specifications, including particle size distribution, compressibility, resistivity, and coefficient of friction measurements, along with the production of graphite bricks for reactor lining applications.

Zentek (NASDAQ:ZTEK) has announced promising preliminary results from its first in vivo tests of an influenza countermeasure candidate using multivalent aptamer technology. The testing, conducted at McMaster University, showed that animals treated with the aptamer lead candidate demonstrated 5x greater survival rates and 80% less weight loss compared to the control group.

The project, supported by a $1.1 million grant from the Government of Canada's Innovative Solutions Canada Testing Stream, aims to develop both prophylactic and therapeutic countermeasures for seasonal influenza (H1N1) and highly pathogenic avian influenza (H5N1). The aptamer countermeasure has shown strong binding affinities for multiple influenza strains (H1, H5, H2, and H3) and demonstrated effective neutralization against H1N1 and H5N1 in vitro.

Zentek (NASDAQ:ZTEK) has announced updates to its slate of director nominees for the upcoming annual general and special meeting scheduled for September 25, 2025. The company has nominated four independent directors: current Board Chair Eric Wallman, current director John Snisarenko, and two new nominees - Matt Fontes and Pete Gettinby.

Current directors Ilse Treurnicht, Lisa Sim, and Wendy Ford will not stand for re-election. The meeting location has been changed to Norton Rose Fulbright Canada LLP's office in Toronto. Shareholders must use the new "BLUE" proxy form for voting, as previous "WHITE" forms will not be counted.

Zentek (Nasdaq:ZTEK) announced the immediate resignation of CEO Greg Fenton, who will transition to lead Altek Advanced Materials, a U.S.-based private company where he holds over 50% equity interest. The company has entered into a non-exclusive licensing agreement LOI with Altek for commercializing Zentek's technologies, including ZenGUARD™, in the United States.

The LOI includes a 5-year initial term with a 5-year renewal option and royalties between 5-8% of net sales. CFO Wendy Ford will serve as interim CEO while the board conducts a comprehensive search for a permanent replacement. Fenton will join Zentek's Advisory Board and continue providing strategic guidance through his Consulting Agreement until March 31, 2026.

Zentek (Nasdaq:ZTEK) announced changes to its Board of Directors. Ilse Treurnicht has resigned from the Board effective immediately but will continue serving on the Zentek Advisory Board. John Snisarenko has been appointed as Company Secretary and Chair of the Corporate Governance, Compensation and Nominating Committee.

Additionally, Lisa Sim will not stand for re-election as director but will join the Advisory Board to continue managing the company's intellectual property portfolio. The Board is reviewing new nomination candidates proposed by shareholders. The company will amend and re-mail proxy voting information for the upcoming annual and special meeting scheduled for September 25, 2025.

Zentek (NASDAQ:ZTEK) announced its subsidiary Albany Graphite Corp. (AGC) has been awarded a $500,000 grant from Ontario's Critical Minerals Innovation Fund for graphite purification and anode development. The project includes $314,500 contribution from AGC and $200,000 in-kind support from Natural Resources Canada.

The project aims to produce 5-6 tonnes of flotation concentrate and involves testing with NRCan's electrothermal fluidized bed reactor. AGC recently achieved a significant milestone with 99.9991% purity in preliminary testing, notably without using chlorine gas. The company is positioning itself in the North American battery supply chain, with potential applications in EV batteries, which require up to 125 kg of graphite per vehicle.

Zentek Ltd. (Nasdaq: ZTEK) has received notification from Nasdaq that it is not compliant with the minimum bid price requirement, as its shares have traded below US$1.00 for 31 consecutive business days. The company has until February 23, 2026 to regain compliance by maintaining a closing bid price of at least US$1.00 for 10 consecutive business days.

If Zentek fails to meet this deadline, it may be eligible for an additional 180-day grace period if it meets other listing requirements and provides written notice to Nasdaq. The notification is not an immediate delisting notice, and the company's shares continue to trade on the Nasdaq Capital Market while management explores options to regain compliance.